Evidence map›Paper›PMID 32140038›Full record

ArticleThe Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology2020

Inhibition of melanogenesis by sodium 2-mercaptoethanesulfonate.

Jeong-Hwan Kim, Chang-Taek Oh, Tae-Rin Kwon, Jong Hwan Kim, Dong-Ho Bak, Hyuk Kim, Won-Seok Park, Beom Joon Kim

Open access · diamondAbstract read
In one paragraph

Article in The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 59% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. 2-Methoxystypandrone fromAntioxidants (Basel, Switzerland) · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Jeong-Hwan KimR&D Unit, AmorePacific Corporation, Yongin 17074, Korea.
Chang-Taek OhDepartment of Dermatology, Chung-Ang University College of Medicine, Seoul 06974, Korea.
Tae-Rin KwonDepartment of Dermatology, Chung-Ang University College of Medicine, Seoul 06974, Korea.
Jong Hwan KimDepartment of Dermatology, Chung-Ang University College of Medicine, Seoul 06974, Korea.
Dong-Ho BakDepartment of Dermatology, Chung-Ang University College of Medicine, Seoul 06974, Korea.
Hyuk KimR&D Unit, AmorePacific Corporation, Yongin 17074, Korea.
Won-Seok ParkR&D Unit, AmorePacific Corporation, Yongin 17074, Korea.
Beom Joon KimDepartment of Dermatology, Chung-Ang University College of Medicine, Seoul 06974, Korea.
Chung-Ang University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sodium 2-mercaptoethanesulfonate (mesna) is a protective agent that is widely used in medicine because of its antioxidant effects. Recently, reactive oxygen species (ROS) were shown to increase pigmentation. Thus, ROS scavengers and inhibitors of ROS production may suppress melanogenesis. Forkhead box-O3a (FoxO3a) is an antimelanogenic factor that mediates ROS-induced skin pigmentation. In this study, we aimed to investigate the whitening effect of mesna and the signaling mechanism mediating this effect. Human melanoma (MNT-1) cells were used in this study. mRNA and protein expression were measured by real-time quantitative PCR and Western blotting analysis to track changes in FoxO3a-related signals induced by mesna. An immunofluorescence assay was performed to determine the nuclear translocation of FoxO3a. When MNT-1 melanoma cells were treated with mesna, melanin production and secretion decreased. These effects were accompanied by increases in FoxO3a activation and nuclear translocation, resulting in downregulation of four master genes of melanogenesis: MITF, TYR, TRP1, and TRP2. We found that mesna, an antioxidant and radical scavenger, suppresses melanin production and may therefore be a useful agent for the clinical treatment of hyperpigmentation disorders.

Indexed as

AntioxidantsHyperpigmentationMesnaSkin lightening preparations

Identifiers

PMID32140038
PMCPMC7043997
OpenAlexW3006891203

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.